SEATTLE– Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TassoOne™ Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation. With this CE Mark, Tasso now expands its capabilities to offer patient-centric, high-volume blood collection solutions for the European market.
The TassoOne Plus is the latest addition to Tasso’s signature line of CE Marked blood collection solutions for dried and liquid samples. Users collect their own blood through an easy, virtually painless process that can be completed at home. The process generates higher volumes and superior sample quality compared to traditional remote blood sampling techniques. The clinical-grade samples fit seamlessly into existing downstream analysis workflows, empowering pharmaceutical companies, healthcare organizations, and academic institutions across the European Economic Area.
“The demand for convenient, patient-centric care is exploding, and Tasso is on a mission to bring high-quality healthcare into homes worldwide,” said Ben Casavant, Ph.D., CEO and co-founder of Tasso. “This CE Mark unlocks clinical-grade liquid blood collection for decentralized clinical trials and home healthcare within the European Union, accelerating and expanding access to care. Regulatory clearances like this one are a testament to the quality and safety of our products.”
